FX007
From Infogalactic: the planetary knowledge core
Jump to: navigation, search
FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain.[1] It is currently in the preclinical stage of development.[2] The drug was licensed by Flexion from AstraZeneca.[3] FX007 has also attracted interest as a potential treatment of osteoarthritis.[1]
See also
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
External links
| Opioids |
|
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anilines | |||||||||||||||||
| NSAIDs |
|
||||||||||||||||
| Cannabinoids | |||||||||||||||||
| Channelergics |
|
||||||||||||||||
| Myorelaxants | |||||||||||||||||
| Others | |||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
Retrieved from "https://infogalactic.com/w/index.php?title=FX007&oldid=722783705"
